<DOC>
	<DOCNO>NCT00372905</DOCNO>
	<brief_summary>Bortezomib may stop growth cancer cell block enzymes need cell growth . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Radiolabeled monoclonal antibody , yttrium Y 90 ibritumomab tiuxetan , find cancer cell carry cancer-killing substance without harm normal cell . Giving bortezomib together rituximab yttrium Y 90 ibritumomab tiuxetan may kill cancer cell . This phase I/II trial study side effect best dose bortezomib give together rituximab yttrium Y 90 ibritumomab tiuxetan see well work treat patient relapsed refractory follicular non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Phase I/II Trial VELCADE Plus Zevalin Patients With Relapsed Refractory Follicular Lymphoma</brief_title>
	<detailed_description>This phase I , dose-escalation study bortezomib follow phase II study . Phase I : - Induction therapy : Patients receive bortezomib IV 3-5 second day 1 , 8 , 15 , 22 , rituximab IV day 8 15 , yttrium Y 90 ibritumomab tiuxetan IV 10 minute day 15 . Cohorts 3-6 patient receive escalate dos bortezomib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . - Consolidation therapy : Beginning 6-7 week complete induction therapy , patient receive bortezomib IV 3-5 second day 1 , 8 , 15 . Treatment repeat every 28 day 3 course absence disease progression unacceptable toxicity . Phase II : Patients receive induction therapy consolidation therapy phase I , bortezomib administer MTD determine phase I . After completion study treatment , patient follow every 3 month 1 year , every 6 month 1 year , annually thereafter . A total 24 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm follicular lymphoma CD20+ time diagnosis subsequently More 4 week since prior rituximab More 3 week since prior anticancer therapy ( 6 week nitrosourea mitomycin C ) More 4 week since prior major surgery More 2 week since prior investigational drug AIDSrelated lymphoma History evidence CNS involvement Pregnant nursing know HIV positivity serious medical psychiatric illness would preclude study participation myocardial infarction within past 6 month congestive heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , ECG evidence acute ischemia active conduction system abnormality know hypersensitivity rituximab , bortezomib , boron , mannitol prior autologous allogeneic stem cell transplantation prior radioimmunoconjugate therapy prior exposure murine antibody prior externalbeam irradiation &gt; 25 % active bone marrow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>follicular lymphoma</keyword>
</DOC>